Uncategorized
Allegro begins phase 2 study for treatment of DME
CHICAGO – At the Ophthalmology Innovation Summit here, Vicken Karageozian, MD, co-founder and CTO of Allegro Ophthalmics, discusses the initiation of the phase 2 study of Luminate, ALG-101, for the treatment of diabetic macular edema.